Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22197991 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL24508761 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12445967 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12281920 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12070762 | 0.97 | KDM4E (0.75) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12014973 | 0.93 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL2952645 | 0.92 | — | — | |
| SCHEMBL14739904 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14740196 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1900654 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022103834-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2020035049-A1 | DEGRADATION AGENTS FOR CYCLIN DEPENDENT KINASE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 中国科学院上海药物研究所 | 2020-02-20 | — | — | WO | disclosed |
| US-20160346236-A1 | COMPOSITIONS AND METHODS FOR MODULATING HEXM1 EXPRESSION | CLEVELAND STATE UNIVERSITY | 2016-12-01 | — | — | US | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| EP-2552923-B1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| WO-2011121105-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-06 | — | — | WO | disclosed |
| US-7968134-B2 | Films comprising a liquid-absorbant inner layer and an impermeable outer layer | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7964226-B2 | Films comprising a liquid-absorbant inner layer and an impermeable outer layer | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964055-B2 | Films comprising a liquid-absorbant inner layer and an impermeable outer layer | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964229-B2 | Films comprising a liquid-absorbant inner layer and an impermeable outer layer | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100166925-A1 | FILMS COMPRISING A LIQUID-ABSORBANT INNER LAYER AND AN IMPERMEABLE OUTER LAYER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100009041-A1 | FILMS COMPRISING A LIQUID-ABSORBANT INNER LAYER AND AN IMPERMEABLE OUTER LAYER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009046-A1 | FILMS COMPRISING A LIQUID-ABSORBANT INNER LAYER AND AN IMPERMEABLE OUTER LAYER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009045-A1 | FILMS COMPRISING A LIQUID-ABSORBANT INNER LAYER AND AN IMPERMEABLE OUTER LAYER | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-7615270-B2 | Multilayer tubal casings; interior layer of polyamideether or polyesterether block copolymer; exterior of polyamides, ethylene-vinyl alcohol copolymer, polyvinylidene chloride, polyolefin | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7381788-B2 | Method for continuous production of polyamide | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TYMP, PIM1, TYMS | KDM4E 911/4885MAPK1 2190/4885HIF1A 4460/4885 |
| US-20160346236-A1 | COMPOSITIONS AND METHODS FOR MODULATING HEXM1 EXPRESSION | HEXB, HEXA, MYADM | KDM4E 3239/4885MAPK1 788/4885HIF1A 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.